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ABSTRACT
Objective To evaluate the effect of secukinumab, an
interleukin-17A inhibitor, on clinical signs and symptoms
and radiographic changes through 2 years in patients
with ankylosing spondylitis (AS).
Methods In the phase III MEASURE 1 study, patients
were randomised to receive intravenous secukinumab
10 mg/kg (at baseline, week 2 and week 4) followed by
subcutaneous secukinumab 150 mg (intravenous
150 mg; n=125) or 75 mg (intravenous 75 mg; n=124)
every four weeks, or matched placebo (n=122). Placebo-
treated patients were re-randomised to subcutaneous
secukinumab 150 or 75 mg from week 16. Clinical
efﬁcacy assessments included Assessment of
SpondyloArthritis international Society 20 (ASAS20)
response rates through week 104. Radiographic changes
at week 104 were assessed using the modiﬁed Stoke
Ankylosing Spondylitis Spine Score (mSASSS).
Results 97 (77.6%) and 103 (83.1%) patients in the
intravenous 150 mg and intravenous 75 mg groups,
respectively, completed week 104. In the full analysis set
(intent-to-treat), ASAS20 response rates at week 104
were 73.7% and 68.0% in the intravenous 150 mg and
intravenous 75 mg groups, respectively. Among patients
with evaluable X-rays who were originally randomised to
secukinumab (n=168), mean change in mSASSS from
baseline to week 104 was 0.30±2.53. Serious adverse
events were reported in 12.2% and 13.4% of patients
in the 150 mg and 75 mg groups, respectively.
Conclusions Secukinumab improved AS signs and
symptoms through 2 years of therapy, with no
unexpected safety ﬁndings. Data from this study suggest
a low mean progression of spinal radiographic changes,
which will need to be conﬁrmed in longer-term
controlled studies.
Trial registration number NCT01358175.
INTRODUCTION
Ankylosing spondylitis (AS), a chronic inﬂamma-
tory disease primarily affecting the axial skeleton,
can be associated with progressive irreversible
structural damage, resulting in functional deterior-
ation.1–3 Long-term treatment goals are to maxi-
mise quality of life through control of signs and
symptoms, prevention of structural damage and
preservation of physical function.4
Tumour necrosis factor (TNF) inhibitors are the
recommended pharmacotherapy for patients with
high disease activity despite treatment with
non-steroidal anti-inﬂammatory drugs (NSAIDs),4 5
based on their proven efﬁcacy in improving signs,
symptoms and physical function.6–10 However, up
to 40% of patients do not respond to or cannot
tolerate TNF inhibitors,11 and loss of efﬁcacy can
occur over time.12 Moreover, their effect on spinal
osteoproliferative changes, a major component of
structural damage in AS, is unclear.13–16
The pro-inﬂammatory cytokine interleukin-17A
(IL-17A) is implicated in various pathophysiological
features of spondyloarthritis, including inﬂammation
and pathogenic bone remodelling.17–29 In
placebo-controlled phase III studies, secukinumab, a
fully human anti-IL-17A monoclonal antibody,
signiﬁcantly improved the signs and symptoms of
psoriasis,30 psoriatic arthritis (PsA),31 and AS.32
Here, we present an update on the efﬁcacy and
safety of secukinumab in patients with AS during
the non-controlled continuation phase of
MEASURE 1 (NCT01358175) through 2 years.
Results of exploratory radiographic endpoints at
2 years are also presented.
METHODS
Study design and patients
Study design and patient eligibility criteria have
been described previously.32 Brieﬂy, patients were
≥18 years of age, with AS fulﬁlling the modiﬁed
New York Criteria, and active disease as deﬁned by
a Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) score of ≥433 and a spinal pain
score of ≥4 cm on a visual analogue scale
(0–10 cm), despite treatment with maximal
tolerated doses of NSAIDs. Patients who previously
received one anti-TNF agent could enrol if they
had an inadequate response or had stopped
treatment for safety or tolerability reasons
(anti-TNF-IR). Patients could continue on stable
doses of sulfasalazine, methotrexate, prednisone
and NSAIDs. Key exclusion criteria are detailed in
the online supplementary materials.
Between 9 November 2011 and 21 January
2013, eligible patients were randomly assigned
(1:1:1) to one of two secukinumab arms or placebo
(randomisation procedures are described in the
online supplementary materials). Patients
randomised to secukinumab received a 10 mg/kg
intravenous infusion at baseline and weeks 2 and 4,
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followed by subcutaneous injections of 150 mg (secukinumab
intravenous 150 mg) or 75 mg (intravenous 75 mg) every four
weeks from week 8; patients in the placebo group were treated
using the same intravenous-to-subcutaneous schedule.
Placebo-treated patients were randomly reassigned (1:1) to
receive secukinumab 150 or 75 mg subcutaneous every four
weeks from week 16 (non-responders) or week 24 (responders),
with response based on Assessment of SpondyloArthritis inter-
national Society 20 (ASAS20) response criteria.3
Procedures and end points
Disease activity and efﬁcacy assessments3 34 35 were conducted at
baseline and throughout the study, with key assessments at weeks
16 and 52 (as previously reported),32 and week 104; further
details are provided in the online supplementary materials.
Lateral view radiographs of the cervical and lumbar spine were
obtained at baseline and week 104. Images were digitised centrally
and patient identiﬁers and temporal indicators removed to ensure
blinding. Radiographs were scored using the modiﬁed Stoke
Ankylosing Spondylitis Spine Score (mSASSS) method (total score
range: 0–72; see online supplementary materials for further
details).36 37 Scoring was conducted by two central, independent
readers, blinded with regard to treatment group and temporal
sequence, who both read each ﬁlm; statistical analyses used the
mean score from the two readers. The top 5% of cases with the
highest between-reader differences for change in radiographic
score were identiﬁed for adjudication, with the two readers per-
forming a third consensus read. Data from X-ray completers
(patients with X-rays at both baseline and week 104) are pre-
sented as mean change from baseline to week 104.
Safety analyses assessed adverse events (AEs), serious AEs and
routine laboratory values. Biochemical investigations were classi-
ﬁed according to the Common Terminology Criteria for Adverse
Events (V.4.03).38 Blood samples were collected at baseline
through week 104 for assessment of secukinumab immunogenicity
using a MesoScale Discovery bridging immunoassay.39
Statistical analysis
Clinical efﬁcacy analyses at week 104 were carried out on data
from patients originally randomised to secukinumab. Statistical
analyses for binary variables up to week 104 used multiple
imputation to account for missing data, while mixed-effect
model repeated measures, with missing data assumed missing at
random, were used for continuous variables (except high-
sensitivity C-reactive protein (hsCRP) was reported as
observed). Data are also reported ‘as observed’ among patients
with evaluable data. Radiographic analyses were assessed in
X-ray completers who were initially randomised to secukinumab
treatment, and in X-ray completers who switched from placebo
to secukinumab at week 16 or 24 (placebo switchers). In each
population, data were pooled between treatment groups.
RESULTS
Patients
Of 371 patients originally randomised to treatment, 97/125
(77.6%) patients in the secukinumab intravenous 150 mg group,
103/124 (83.1%) in the intravenous 75 mg group and 90/122
(73.8%) in the placebo group (no placebo given beyond week
24) completed week 104. AEs (6.4% of patients), lack of
efﬁcacy (4.4%) and patient/guardian decision (5.8%) were the
main reasons for discontinuation among secukinumab-treated
patients (see online supplementary ﬁgure S1).
Demographic and baseline characteristics have been reported
previously.32 Mean time since diagnosis in the three randomised
groups was 6.5–8.3 years, mean total BASDAI scores were 6.1–6.5
and median hsCRP levels were 7.4–9.2 mg/L. Approximately 73%
of patients were anti-TNF-naive.
Concomitant medications through 104 weeks were very
similar to 52 weeks and baseline, and included sulfasalazine
(35.0%), methotrexate (15.8%), systemic glucocorticoids
(19.7%) and NSAIDs (93.6%).
Clinical efﬁcacy
Among patients who continued on secukinumab treatment,
ASAS20 and ASAS40 response rates similar to those achieved at
weeks 16 and 5232 were observed at week 104 (ﬁgure 1A, B).
ASAS20/40 response rates at week 104 (with multiple
imputation of missing values) were 73.7/55.7%, respectively, in
the secukinumab intravenous 150 mg group and 68.0/48.5% in
the intravenous 75 mg group (table 1). Response rates using
observed data are reported in table 1. Improvements consistent
with those reported previously at weeks 16 and 5232 were also
observed in total BASDAI score (ﬁgure 1C) and all other
secondary end points at week 104 (table 1).
In prespeciﬁed subgroup analyses, ASAS20 and ASAS40
response rates in both anti-TNF-naive and anti-TNF-IR patients
were higher with secukinumab than placebo at week 16 (see
online supplementary ﬁgure S2). Observed data showed that
59/69 (85.5%) and 47/65 (72.3%) anti-TNF-naive patients in
the secukinumab intravenous 150 mg and intravenous 75 mg
groups, respectively, achieved an ASAS20 response at week 104;
an ASAS40 response was achieved by 48/69 (69.6%) and 34/65
(52.3%) patients, respectively. In anti-TNF-IR patients, 10/18
(55.6%) and 15/21 (71.4%) patients achieved an ASAS20
response in the intravenous 150 mg and intravenous 75 mg
groups, respectively, while 8/18 (44.4%) and 12/21 (57.1%)
patients achieved an ASAS40 response.
Radiographic ﬁndings
Of the 97 patients in the secukinumab intravenous 150 mg group
and 103 patients in the intravenous 75 mg group who completed
week 104, 86 (88.7%) and 82 (79.6%), respectively, had evaluable
X-rays at baseline and week 104 (X-ray completers) meeting
predeﬁned statistical analysis windows. Baseline characteristics of
the X-ray completer cohort were similar between dose groups
(table 2) and to those previously reported in the overall
population.32 Overall, 104 (61.9%) X-ray completers had
syndesmophytes at baseline and 105 (62.5%) had hsCRP >5 mg/
L. Baseline characteristics of the 89 placebo-switcher X-ray
completers (see online supplementary table S1) were similar to
those originally randomised to secukinumab.
Figure 2 shows the cumulative probability plot for change
from baseline in mSASSS at week 104 among X-ray completers
randomised to secukinumab at baseline. The change in mSASSS
(mean±SD) over 104 weeks was 0.30±2.53 in the pooled
secukinumab group, 0.30±1.94 in the intravenous 150 mg
group and 0.31±3.04 in the intravenous 75 mg group (table 3).
Changes among placebo switchers were 0.54±2.45 (pooled),
0.44±2.09 (150 mg) and 0.64±2.79 (75 mg) (see online
supplementary table S2 and ﬁgure S3). The smallest detectable
change (SDC) was 1.838 and 2.814 at an 80% and 95% level
of agreement, respectively. As deﬁned by SDC at the 80% level
of agreement, a large proportion of patients (>80%) had no
spinal radiographic progression. The Bland-Altman plot in
online supplementary ﬁgure S4 shows the level of agreement
between the two readers; variability was observed, particularly
when an mSASSS change of >0 was recorded. The intraclass
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correlation coefﬁcient (ICC) score for agreement between
readers was 0.570 for change in mSASSS.
Baseline mSASSS was higher among patients with known
predictors of radiographic progression compared with those
without (table 3). Mean mSASSS change at week 104 among
X-ray completers randomised to secukinumab was higher in
males than females, in those with baseline syndesmophytes
versus those without, in patients with elevated versus normal
baseline hsCRP levels and in smokers versus non-smokers (table
3). Among the X-ray completers who had no syndesmophytes at
baseline and who were randomised to secukinumab, 61/64
(95.3%), remained free from syndesmophytes at week 104. Of
the 104 X-ray completers with syndesmophytes at baseline,
approximately 70% did not develop additional syndesmophytes
through week 104 (see online supplementary table S3).
Safety
The most common AEs with secukinumab were nasopharyngitis,
diarrhoea, headache, upper respiratory tract infections and
pharyngitis (table 4). Discontinuations due to AEs were infre-
quent. The incidence of serious AEs was low, and similar
between the two secukinumab groups (table 4; see online
supplementary table S4).
One death was reported among secukinumab-treated patients
throughout the study; on day 706, a patient in the intravenous
75 mg group with a history of arterial hypertension and
smoking died due to acute respiratory failure secondary to
cardiac failure and pulmonary ﬁbrosis. No suicides or
suicidality-related AEs were reported among secukinumab-
treated patients.
Candida infections were reported in four secukinumab-
treated patients (0.7 cases per 100 patient-years of secukinumab
exposure); two oral candidiasis (one in each dose group), one
cutaneous Candida infection (150 mg group) and one genital
candidiasis (75 mg group). All four events were considered mild
and non-serious, resolved spontaneously or with standard anti-
fungal therapy, and did not result in study discontinuation.
Herpes viral infections — mainly oral herpes and herpes zoster
infections — were reported by 8.3% of patients in the 150 mg
group and 2.2% in the 75 mg group. All cases were non-serious.
One led to treatment discontinuation (herpes zoster infection in
the 150 mg group).
Grade 3 neutropenia occurred at a single visit in each of three
patients receiving secukinumab 75 mg and one receiving
secukinumab 150 mg. Grade 4 neutropenia was reported in one
patient (75 mg group) at a single visit. None of these events led
to treatment interruption or discontinuation. One grade 3 case
was associated with a non-serious upper respiratory tract
infection.
Crohn’s disease was reported as a non-serious AE in four
patients in the 75 mg group (of whom two had a history of
Crohn’s disease and one a history of a polyp and colon
adenoma) and one patient in the 150 mg group, equivalent to
0.8 cases per 100 patient-years of secukinumab exposure. Two
patients (one in each group; one with a history of Crohn’s
disease) discontinued because of an AE of Crohn’s disease. A
history of uveitis was reported in 62 (16.7%) patients at
baseline. An AE of uveitis was reported in 12 patients (seven
with history of uveitis) on secukinumab, equivalent to 2.0 cases
per 100 patient-years of secukinumab exposure. One was a
serious AE (150 mg group); this resolved and did not require
discontinuation of study treatment. Nineteen (5.1%) patients
had a history of psoriasis. Five patients reported an AE of
psoriasis during the study (two on 75 mg, three on 150 mg),
Figure 1 Summary of selected clinical efﬁcacy end points through
week 104 for patients randomised to secukinumab at baseline.
Assessment of SpondyloArthritis international Society response criteria
(ASAS20) (A) and ASAS40 (B) response rates, and mean change in total
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (C)
over time to week 104 is shown. Multiple imputation applied to handle
missing data for ASAS20 and ASAS40, mixed-effects model repeated
measures used for BASDAI. Patients received a 10 mg/kg loading dose
of secukinumab at baseline and weeks 2 and 4, before receiving
indicated dose of secukinumab subcutaneously every four weeks from
week 8.
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three of which were described as worsening or exacerbation of
psoriasis. No psoriasis AEs were considered serious or required
treatment interruption or discontinuation.
Four secukinumab-treated patients (two in each dose group)
had cardiovascular events adjudicated as meeting major adverse
cardiac event (MACE) criteria: three myocardial infarctions and
one ischaemic stroke (see online supplementary table S5). None
of these events led to treatment discontinuation. The incidence
of MACE was 0.6 per 100 patient-years of secukinumab
exposure.
Four cases of malignant/unspeciﬁed tumours were reported
(0.6 per 100 patient-years of secukinumab exposure), all before
week 52, and have been described previously.32
Treatment-emergent anti-secukinumab antibodies were
detected through week 104 in two patients in the secukinumab
150 mg group; no neutralising antibodies were detected and
neither patient experienced a loss of ASAS20 response.
DISCUSSION
This analysis demonstrates that secukinumab improves the
clinical signs and symptoms of AS through 2 years of continued
therapy. Secukinumab was effective in both anti-TNF-naive and
anti-TNF-IR patients, although absolute response rates were
generally higher in anti-TNF-naive patients. In contrast to the
anti-TNF-naive subgroup, ASAS20 and ASAS40 response rates
were highest with secukinumab intravenous 75 mg in
anti-TNF-IR patients. However, these results should be viewed
in the context of the relatively small number of anti-TNF-IR
patients, particularly at week 104, and the heterogeneity of this
subpopulation, which comprised patients who failed anti-TNF
treatment for any one of several reasons, including lack of
primary or secondary efﬁcacy, or intolerance. Overall, given the
lack of therapeutic alternatives, these ﬁndings indicate that
secukinumab may address an unmet clinical need in
Table 1 Summary of efficacy data at week 104 among patients randomised to secukinumab at baseline
Imputed Observed
Efficacy end point
Secukinumab
intravenous 150 mg
(n=125)
Secukinumab
intravenous 75 mg
(n=124)
Secukinumab
intravenous 150 mg
Secukinumab
intravenous 75 mg
ASAS20 response 73.7% 68.0% 69/87 (79.3%) 62/86 (72.1%)
ASAS40 response 55.7% 48.5% 56/87 (64.4%) 46/86 (53.5%)
hsCRP, median change from baseline
(min, max) (mg/L)
N/A N/A –4.20 (–143.6, 50.0)
(n=88)
–2.7 (–97.5, 30.2)
(n=87)
ASAS5/6 response 57.9% 52.2% 56/87 (64.4%) 49/86 (57.0%)
BASDAI, mean change from baseline –2.93 (0.18) –2.75 (0.18) –3.41 (2.12)
(n=87)
–3.04 (1.81)
(n=86)
SF-36 PCS score, mean change from baseline 6.88 (0.68) 6.36 (0.69) 8.06 (8.08)
(n=87)
7.41 (6.83)
(n=85)
ASQoL score, mean change from baseline –4.38 (0.45) –4.34 (0.45) –4.82 (4.83)
(n=86)
–4.58 (4.44)
(n=85)
ASAS partial remission 25.6% 19.3% 28/87 (32.2%) 20/86 (23.3%)
Binary variables are reported using multiple imputation (percentage of responders) to account for missing data and as observed data (n/m (%), where n=number of patients with response
and m=number of patients with evaluable data). For continuous variables, mean change from baseline is reported as least-square mean change (SE) where mixed-effects model repeated
measures analysis was performed and as observed data (SD). Patients received a 10 mg/kg loading dose of secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of
secukinumab subcutaneously every four weeks from week 8.
ASAS, Assessment of SpondyloArthritis international Society response criteria; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;
hsCRP, high-sensitivity C-reactive protein; N/A, not available; SF-36 PCS, Short Form-36 physical component summary.
Table 2 Baseline characteristics of the X-ray completer cohort
randomised to secukinumab at baseline
Characteristic
Secukinumab
intravenous
150 mg
(n=86)
Secukinumab
intravenous
75 mg
(n=82)
Age, mean (SD) years 39.6 (12.0) 42.4 (13.1)
Male gender, n (%) 63 (73.3) 60 (73.2)
Weight, mean (SD) kg 75.2 (16.4) 78.4 (19.3)
Time since AS diagnosis, mean (SD)
years
6.6 (7.0) 7.8 (8.9)
HLA-B27 positive, n (%) 64 (74.4) 72 (87.8)
Current smoker, n (%) 25 (29.1) 17 (20.7)
Anti-TNF-naive, n (%) 60 (69.8) 62 (75.6)
Medication use at baseline, n (%)
Methotrexate 14 (16.3) 12 (14.6)
Sulfasalazine 27 (31.4) 32 (39.0)
Glucocorticoids 13 (15.1) 10 (12.2)
hsCRP, median (min, max), mg/L 7.8 (0.2, 147.7) 9.7 (0.4, 100.0)
Elevated hsCRP >5 mg/L, n (%) 55 (64.0) 50 (61.0)
Total BASDAI, mean (SD) 6.2 (1.6) 6.0 (1.5)
BASFI, mean (SD) 5.6 (2.2) 5.4 (2.0)
BASMI (linear), mean (SD) 3.9 (1.8) 4.2 (1.7)
mSASSS, mean (SD) 9.6 (16.6) 10.8 (16.7)
Syndesmophyte present, n (%) 51 (59.3) 53 (64.6)
Total back pain, mean (SD) 63.9 (17.2) 63.3 (18.6)
Patient’s global assessment of disease
activity, mean (SD)
64.6 (17.7) 60.5 (18.6)
Data are n (%), mean (SD), or median (minimum–maximum).
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;
BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing
Spondylitis Metrology Index; HLA, human leucocyte antigen; hsCRP, high-sensitivity
C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; TNF,
tumour necrosis factor.
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anti-TNF-IR patients, as well as providing a high level of efﬁcacy
as ﬁrst-line therapy in anti-TNF-naive patients.
Prevention of structural damage is a long-term treatment goal
in AS. The effect of anti-TNFs on radiographic progression in AS
is unclear. mSASSS changes of 0.8–0.9 over 2 years have been
reported with TNF inhibitors in AS clinical trials compared with
0.9–1.3 in respective matched biologic-naive historical control
cohorts from the Outcomes in AS International Study
(OASIS).14–16 Authors concluded that the results do not provide
evidence that anti-TNF therapy inhibits radiographic progression
over 2 years. More recent studies have suggested that longer-term
(approximately 8 years) treatment with an anti-TNF or earlier
treatment initiation may be required to demonstrate an effect on
radiographic progression.40 41 In the present study, the mean
change in mSASSS through 2 years of secukinumab therapy was
0.30 (SD 2.53) overall, and 0.38–0.52 among patients with
known predictors of radiographic progression at baseline, such
as syndesmophytes or elevated CRP.42 Comparisons between
these ﬁndings and those reported in the aforementioned studies
and historical cohorts cannot be made because of differences in
study designs and populations. Data from OASIS are from a
period when treatment options were limited, and early TNF
inhibitor trials are likely to have had more severe disease than
those enrolled in MEASURE 1 and other recent placebo-
controlled trials. Indeed, patients with evidence of radiographic
progression are now more likely to be prescribed an approved
TNF inhibitor than enter a clinical trial in which they might be
randomised to placebo, and the anti-TNF trials included patients
with longer disease duration (∼10–11 years vs ∼7 years in X-ray
completers)8 14–16 and more severe radiographic disease at
baseline (mSASSS ∼16–2013–16 vs ∼10) than in our study.
Agreement between readers in mSASSS change was modest, with
an ICC within the expected range of those reported from other
studies.13–15 43 The Bland-Altman plot indicates that there is
inter-reader variability, particularly where changes in mSASSS
have occurred. The low overall rate of progression seen with
secukinumab requires further exploration in long-term controlled
studies before deﬁnite conclusions can be reached on whether
anti-IL-17A therapy is effective in inhibiting mSASSS progression
in patients with AS. Comparing radiographic changes associated
with secukinumab with the historical cohorts, matched in terms
of baseline disease, is also a possible area of future research.
Secukinumab showed an acceptable safety proﬁle over 622.5
patient-years of exposure, with no new safety signals or
unexpected safety ﬁndings compared with the ﬁrst 52 weeks32
or with the safety proﬁle reported in PsA and psoriasis.30 31 The
incidence of AEs was higher with 150 mg than with 75 mg,
driven primarily by non-serious infections. Serious infections
were infrequent in both secukinumab groups. Candida
infections, a known risk with IL-17 inhibitors given the role of
IL-17 in mucosal defence,44 were infrequent, mild and clinically
manageable with antifungals. No dose dependence was observed
for other safety risks. All four patients who reported MACE
events on secukinumab treatment had pre-existing cardiovascu-
lar risk factors. The incidence of MACE in our study (0.6 per
100 patient-years) is consistent with reported data in AS.45
Spondyloarthritis is often associated with extra-articular
manifestations such as uveitis, psoriasis and inﬂammatory bowel
disease.2 Patients with previous or stable presentation of these
conditions could enrol in MEASURE 1. The incidence of extra-
articular manifestations reported as AEs in our study was low
and consistent with expected rates in AS. IL-17A has been
reported to have either a pathogenic or a protective role in
Crohn’s disease.46 47 The incidence of Crohn’s disease in the
present study (0.8 per 100 patient-years of secukinumab expos-
ure) compares with reported rates of 0.2–1.3 per 100 patient-
years for TNF inhibitors in the AS population.48
Limitations of this analysis include the lack of comparator
group beyond week 16, limiting interpretation of long-term
ﬁndings to a comparison between secukinumab doses and to
longitudinal evaluation. Despite the use of accepted statistical
methods to account for missing data during the continuation
period of the study, there remains a possible bias from the fact
that patients who stay on study are those who do well on study
treatment. Nevertheless, retention rates were high throughout
the study and only 4.4% of patients withdrew because of lack of
efﬁcacy during the 2-year period. The slow nature of radio-
graphic disease progression in AS means long follow-up periods
are required to show measureable changes. This prohibits the
inclusion of a placebo comparator and can introduce confound-
ing effects of concomitant treatment with other drugs that
inﬂuence radiographic progression.49 Although blinded to
treatment groups and sequence, readers were aware that all
patients received secukinumab, possibly introducing an
observational bias.
In conclusion, these longitudinal results from MEASURE 1
demonstrate that secukinumab provides similar levels of
improvement in the clinical signs and symptoms of AS at 2 years
as those previously reported during the short-term
placebo-controlled period and provide the ﬁrst uncontrolled
Figure 2 Cumulative probability plot
for change from baseline in the
modiﬁed Stoke Ankylosing Spondylitis
Spine Score (mSASSS) at week 104 in
X-ray completers randomised at
baseline to secukinumab (observed
data). X-ray completers are those
patients with X-rays at both baseline
and at week 104. Patients received a
10 mg/kg loading dose of
secukinumab at baseline and weeks 2
and 4, before receiving indicated dose
of secukinumab subcutaneously every
four weeks from week 8.
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data on spinal radiographic progression in patients with AS
under treatment with an IL-17A inhibitor. Long-term controlled
studies are needed to evaluate whether secukinumab inhibits the
progression of structural manifestations of AS.
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Table 4 Incidence of treatment-emergent adverse events (AEs)
during the entire treatment period through to week 104
Variable
Any
secukinumab
150 mg
(n=181)*
Any
secukinumab
75 mg
(n=179)*
Any
secukinumab
pooled
(n=360)*
Exposure to study
treatment (days)†
621.3 (187.5) 642.0 (180.9) 631.6 (184.3)
Number of patients with event (%)
Any AE 157 (86.7) 144 (80.4) 301 (83.6)
Serious AE‡ 22 (12.2) 24 (13.4) 46 (12.8)
Any AE leading to
discontinuation§
17 (9.4) 8 (4.5) 25 (6.9)
Infection or
infestation¶
110 (60.8) 100 (55.9) 210 (58.3)
Common AEs (seen in >5% of patients on secukinumab), n (%)
Nasopharyngitis 44 (24.3) 35 (19.6) 79 (21.9)
Diarrhoea 25 (13.8) 22 (12.3) 47 (13.1)
Headache 22 (12.2) 20 (11.2) 42 (11.7)
Upper respiratory tract
infection
17 (9.4) 21 (11.7) 38 (10.6)
Pharyngitis 21 (11.6) 12 (6.7) 33 (9.2)
Dyslipidaemia 14 (7.7) 16 (8.9) 30 (8.3)
Influenza 17 (9.4) 13 (7.3) 30 (8.3)
Oropharyngeal pain 16 (8.8) 13 (7.3) 29 (8.1)
Arthralgia 13 (7.2) 11 (6.1) 24 (6.7)
Back pain 13 (7.2) 7 (3.9) 20 (5.6)
Leucopenia 8 (4.4) 12 (6.7) 20 (5.6)
Cough 10 (5.5) 9 (5.0) 19 (5.3)
Nausea 10 (5.5) 9 (5.0) 19 (5.3)
AEs of special interest, n (exposure-adjusted incidence rate per 100 patient-years)
Candida infections 2 (0.7) 2 (0.6) 4 (0.7)
Serious infections 3 (1.0) 3 (1.0) 6 (1.0)
Crohn’s disease 1 (0.3) 4 (1.3) 5 (0.8)
Major adverse cardiac
events (adjudicated)
2 (0.7) 2 (0.6) 4 (0.6)
Malignancy 3 (1.0) 1 (0.3) 4 (0.6)
Neutropenia
(preferred term)
9 (3.1) 14 (4.8) 23 (3.9)
*Includes patients randomised to secukinumab at baseline and patients who were
randomised to placebo who switched to secukinumab at weeks 16 or 24.
†Reported as mean (SD).
‡Serious AEs also include deaths.
§Up to week 104; an additional two patients discontinued secukinumab due to any AEs
after week 104.
¶System organ class category.
Table 3 mSASSS in the X-ray completer cohort randomised to
secukinumab at baseline
Variable
Secukinumab
intravenous
150 mg
Secukinumab
intravenous
75 mg
Secukinumab
pooled
Overall population
Patients (n) 86 82 168
Baseline 9.63 (16.63) 10.84 (16.69) 10.22 (16.62)
Change at
week 104
0.30 (1.94) 0.31 (3.04) 0.30 (2.53)
Patients with syndesmophytes at baseline
Patients (n) 51 53 104
Baseline 16.12 (19.09) 16.69 (18.32) 16.41 (18.61)
Change at
week 104
0.49 (2.50) 0.45 (3.77) 0.47 (3.20)
Patients without syndesmophytes at baseline
Patients (n) 35 29 64
Baseline 0.17 (0.56) 0.16 (0.40) 0.16 (0.49)
Change at
week 104
0.01 (0.19) 0.03 (0.33) 0.02 (0.26)
Elevated hsCRP
Patients (n) 55 50 105
Baseline 11.57 (17.69) 14.22 (19.16) 12.83 (18.36)
Change at
week 104
0.48 (2.25) 0.46 (3.08) 0.47 (2.66)
Normal hsCRP
Patients (n) 31 32 63
Baseline 6.18 (14.19) 5.56 (10.04) 5.87 (12.16)
Change at
week 104
–0.03 (1.16) 0.06 (3.00) 0.02 (2.27)
Male
Patients (n) 63 60 123
Baseline 11.91 (18.57) 13.70 (18.44) 12.78 (18.45)
Change at
week 104
0.19 (2.01) 0.58 (3.44) 0.38 (2.79)
Female
Patients (n) 23 22 45
Baseline 3.39 (6.44) 3.05 (5.68) 3.22 (6.02)
Change at
week 104
0.59 (1.73) –0.46 (1.23) 0.08 (1.58)
Smokers (at baseline)
Patients (n) 25 17 42
Baseline 13.10 (19.45) 10.88 (9.20) 12.20 (16.00)
Change at
week 104
−0.18 (1.71) 1.56 (4.00) 0.52 (2.95)
Non-smokers (at baseline)
Patients (n) 61 65 126
Baseline 8.21 (15.28) 10.83 (18.21) 9.56 (16.84)
Change at
week 104
0.49 (2.00) –0.02 (2.67) 0.23 (2.38)
n indicates number of patients with evaluable paired X-ray data at both baseline and
week 104 (X-ray completers). Data shown as mean (SD). mSASSS ranges from 0 to 72,
with higher scores indicating greater radiographic damage. Patients received 10 mg/kg
secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of
secukinumab subcutaneously every four weeks from week 8.
hsCRP, high-sensitivity C-reactive protein; mSASSS, modified Stoke Ankylosing
Spondylitis Spine Score.
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